The record-setting Alexandria lab lease in San Diego showcases how biotech has few big tenants left to take empty spaces.

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

Incyte Corporation INCY reported second-quarter 2025 adjusted earnings of $1.57 per share, which beat the Zacks Consensus ...

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Novartis moves to block cancer drug generic in US ...

Ninety percent of parents, expectant parents said they'd want to know early about SMA, and 80% said not screening newborns ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

People in 15 regions across the U.S. will soon benefit from the American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative™, designed to improve treatment of the interconnected ...

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may ...